Tag: ASX: CAN
Cann Group expects record revenue growth of 111% in FY23
Pharmaceutical company Cann Group Limited announced its FY23 unaudited results, with its operating revenue expected to be approximately $13.5 million, representing growth of 111 per cent or 2.1 times compared to the prior year revenue.
Featured Article
Building resilience as manufacturing requirements become more complex
The industrial machinery and heavy equipment manufacturing sector is critical not only for its direct outputs, machines, and equipment that pave the way for construction, agriculture and manufacturing but also for its crucial role in economic development and innovation.
